Clinical human trials begin for COVID-19 vaccine in China

[JSCh]

https://twitter.com/x/status/1414544699520557058

Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX

Gavi, the Vaccine Alliance announced today that it had signed advance purchase agreements (APAs) with Sinopharm for its “BBIBP-CorV” inactivated virus vaccine against COVID-19 as well as with Sinovac for its inactivated virus vaccine against COVID-19, “CoronaVac”.

www.gavi.org

 

[JSCh]

https://twitter.com/x/status/1415503653058740224

 

[JSCh]

https://twitter.com/x/status/1415513532796346374

 

[JSCh]

https://twitter.com/x/status/1415544865232867333

People's Daily, China @PDChina
China state-affiliated media

#Brazil approved the two-dose inactivated #COVID19 vaccine developed by the Chinese Academy of Medical Sciences for phase-3 clinical trial in the country, announced Brazilian authorities on Wednesday. A total of 7,992 volunteers will participate in the clinical trial.


1:32 PM · Jul 15, 2021

 

[JSCh]

This is for clinical treatment of COVID-19, not vaccine.

https://twitter.com/x/status/1415630927968055297

Covid19Crusher @Covid19Crusher​

Jul 15, 2021​

​

Fosun Pharma, a large Chinese pharma group has bought the rights to antiandrogen Proxalutamide for India and Africa, adding to the credibility of that spectacularly effective Covid treatment that has the potential to change the course of the pandemic.​

​

There is question of credibility because the reported clinical trial result is just too good.

Science magazine has an news article on this back in 7 Jul, 2021.

Science | AAAS

www.sciencemag.org

 

[JSCh]

https://twitter.com/x/status/1416005051466747907

 

[JSCh]

China Zhifei's COVID shot largely retains effect against Delta variant-lab study

A COVID-19 vaccine developed by a unit of China's Chongqing Zhifei Biological Products (300122.SZ) largely retained its neutralising effect against the Delta variant but there was a slight reduction, Chinese researchers found in a laboratory study.

www.reuters.com

 

[JSCh]

https://twitter.com/x/status/1417097135670140930

Yicai Global 第一财经 @yicaichina
China state-affiliated media

China’s Kangtai Biological Partners With Startup to Develop mRNA Vaccines https://bit.ly/3zg9EU2


8:21 PM · Jul 19, 2021

 

[JSCh]

https://twitter.com/x/status/1417648517569413123

Hilda Bastian, PhD @hildabast

A larger trial now registered for this mixed Covid vax schedule: 6 mths after full inactivated IMBCAMS course, boost with Stemirna mRNA or another IMBCAMS (not randomized) https://clinicaltrials.gov/ct2/show/NCT04944381… (IMBCAMS is in phase 3; Stemirna, not yet)

Small mixed vaccine schedule trial (20 people) registered in China: mRNA after 2 doses inactivated vax http://chictr.org.cn/showprojen.aspx?proj=128920…Can't be 100% sure which vaxes, but Shanghai East so I'm pretty sure it's IMBCAMS & Stemirna as here​

​

https://medrxiv.org/content/10.1101/2021.05.17.21257134v1… (Both still in phase 3)​

​

8:51 AM · Jul 21, 2021

 

[JSCh]

https://twitter.com/x/status/1417753024693514243

CEPI @CEPIvaccines
Jul 21, 2021

We've announced our 13th #COVID19 vaccine partnership with ZerunBio

The new partnership—which forms part of our effort to advance “next-generation” COVID-19 vaccines within our $3.5bn plan— marks a critical addition to our growing portfolio (1/5)

Up to US $13.1 million will be provided by CEPI to support Phase I clinical trials and scale-up of ZerunBio’s scalable and thermostable #COVID19 prototype vaccine. Previous preclinical studies show that it induces a robust immune response. (2/5)

 

[JSCh]

https://twitter.com/x/status/1418450866131058689

Science Magazine @ScienceMagazine

A new protein subunit vaccine candidate for #COVID19 elicits antibody responses in large and small animals—and, in hamsters, prevents both infections and the transmission of #SARSCoV2 to unvaccinated animals. https://fcld.ly/t3p81b4 @ScienceTM #VaccineDesign


2:00 PM · Jul 23, 2021

 

[JSCh]

https://twitter.com/x/status/1420296760602374146

https://twitter.com/x/status/1419923006487502848

 

[JSCh]

https://twitter.com/x/status/1423203095564128263

Global Times @globaltimesnews
China state-affiliated media

China's #vaccine producer #Sinopharm discovers a potent antibody against #Delta variant. Known as the "biological missile", it could be effective in short-term preventive and early treatment of the new variant of COVID-19. https://bit.ly/37mDeLK

China's vaccine producer Sinopharm discovers potent antibody against Delta variant, effective in early treatment of COVID-19 - Global Times

www.globaltimes.cn

4:43 PM · Aug 5, 2021

https://twitter.com/x/status/1420351180887130118

 

[JSCh]

https://twitter.com/x/status/1423467612684447745

People's Daily, China @PDChina
China state-affiliated media

China's #Sinovac will submit an application in several countries for clinical research and emergency use on vaccines targeting Gamma and Delta variants, Sinovac CEO Yin Weidong said Thursday.


10:15 AM · Aug 6, 2021

 

[JSCh]

https://twitter.com/x/status/1423461321157144577

People's Daily, China @PDChina
China state-affiliated media

A booster shot 6 months after #CanSino vaccine dose increased level of neutralizing antibodies by about 8 times, China's CanSino said Thursday citing latest study. The vaccine brings similar level of neutralizing antibody against 9 strains including Delta.

https://twitter.com/x/status/1423531798953435136